{"id":"mk-4280","safety":{"commonSideEffects":[{"rate":null,"effect":"Lymphopenia"},{"rate":null,"effect":"Infection"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Diarrhea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"CCR4 is highly expressed on regulatory T cells (Tregs) and certain activated T cell populations. By blocking CCR4, MK-4280 depletes Tregs from tumors, reducing immunosuppression and allowing enhanced anti-tumor immune responses. This mechanism aims to enhance the efficacy of checkpoint inhibitors and other immunotherapies.","oneSentence":"MK-4280 is a selective antagonist of the chemokine receptor CCR4 that reduces the recruitment and activation of T regulatory cells to the tumor microenvironment.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:21:42.174Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Advanced or metastatic solid tumors (in combination with checkpoint inhibitors)"}]},"trialDetails":[{"nctId":"NCT06036836","phase":"PHASE2","title":"Study of Favezelimab Coformulated With Pembrolizumab (MK-4280A) in Participants With Selected Solid Tumors (MK-4280A-010)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2023-09-29","conditions":"Solid Tumor, Cutaneous Squamous Cell Carcinoma, Endometrial Cancer","enrollment":163},{"nctId":"NCT03486873","phase":"PHASE3","title":"Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2018-08-21","conditions":"Solid Tumors, Hematologic Malignancies","enrollment":3500},{"nctId":"NCT03598608","phase":"PHASE1, PHASE2","title":"Study to Evaluate the Safety and Efficacy of a Combination of Favezelimab (MK-4280) and Pembrolizumab (MK-3475) in Participants With Hematologic Malignancies (MK-4280-003)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2018-10-17","conditions":"Hodgkin Disease, Lymphoma, Non-Hodgkin, Lymphoma, B-Cell","enrollment":137},{"nctId":"NCT05508867","phase":"PHASE2","title":"A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Physician's Choice Chemotherapy in PD-(L)1-refractory, Relapsed or Refractory Classical Hodgkin Lymphoma (MK-4280A-008)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2022-10-18","conditions":"Hodgkin Lymphoma","enrollment":203},{"nctId":"NCT05600309","phase":"PHASE3","title":"A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Standard of Care in Subjects With Previously Treated Metastatic PD-L1 Positive Colorectal Cancer (MK-4280A-007)-China Extension Study","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2022-06-14","conditions":"Colorectal Cancer","enrollment":94},{"nctId":"NCT05064059","phase":"PHASE3","title":"A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Standard of Care in Subjects With Previously Treated Metastatic PD-L1 Positive Colorectal Cancer (MK-4280A-007)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2021-11-10","conditions":"Colorectal Cancer","enrollment":441},{"nctId":"NCT03516981","phase":"PHASE2","title":"A Study of Biomarker-Directed, Pembrolizumab (MK-3475) Based Combination Therapy for Advanced Non-Small Cell Lung Cancer (MK-3475-495/KEYNOTE-495)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2018-10-01","conditions":"Advanced Non-Small Cell Lung Cancer","enrollment":245},{"nctId":"NCT02720068","phase":"PHASE1","title":"Study of Favezelimab (MK-4280) as Monotherapy and in Combination With Pembrolizumab (MK-3475) With or Without Chemotherapy or Lenvatinib (MK-7902) AND Favezelimab/Pembrolizumab (MK-4280A) as Monotherapy in Adults With Advanced Solid Tumors (MK-4280-001)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2016-05-02","conditions":"Neoplasms","enrollment":481}],"_emaApprovals":[],"_faersSignals":[{"count":1,"reaction":"ATRIAL FIBRILLATION"},{"count":1,"reaction":"DERMATITIS"},{"count":1,"reaction":"HEPATITIS"},{"count":1,"reaction":"PANCREATITIS"},{"count":1,"reaction":"SEPTIC SHOCK"}],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Favezelimab"],"phase":"phase_3","status":"active","brandName":"MK-4280","genericName":"MK-4280","companyName":"Merck Sharp & Dohme LLC","companyId":"merck-sharp-dohme-llc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"MK-4280 is a selective antagonist of the chemokine receptor CCR4 that reduces the recruitment and activation of T regulatory cells to the tumor microenvironment. Used for Advanced or metastatic solid tumors (in combination with checkpoint inhibitors).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}